Understanding challenges and support for cancer care in young patients with Ewing sarcoma and osteosarcoma
Official title: Barriers and Facilitators for Delivery of Guideline-Concordant Care for Adolescents and Young Adults with Ewing Sarcoma and Osteosarcoma
Funded at University of California at Davis · NIH-10864493 · Data updated 2026-11-12
This study is looking at what makes it easier or harder for teenagers and young adults with Ewing sarcoma and osteosarcoma to get the cancer care they need, especially for those who might not have the same access to treatment, and it aims to come up with ways to improve their care.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | August 1, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $281,565 |
| NIH project number | 1K08CA288912-01 |
| Project ID | NIH-10864493 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adolescents and young adults aged 15 to 39 who have been diagnosed with Ewing sarcoma or osteosarcoma.
✕Less likely to help
Patients outside the age range of 15 to 39 or those diagnosed with cancers other than Ewing sarcoma or osteosarcoma may not benefit from this research.
What this research studies
This research investigates the barriers and facilitators that affect the delivery of standardized cancer care for adolescents and young adults diagnosed with Ewing sarcoma and osteosarcoma. By employing an implementation mapping process, the study aims to identify obstacles to receiving guideline-concordant care and develop strategies to improve access to this essential treatment. The research focuses on understanding the unique needs of this patient population, particularly those who are underserved or face socioeconomic challenges. Ultimately, the goal is to create an actionable plan to enhance the quality of care for these young patients.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and quality of care for adolescents and young adults with Ewing sarcoma and osteosarcoma.
How similar studies have gone: Previous research has indicated that addressing barriers to guideline-concordant care can lead to improved outcomes, suggesting that this approach has potential for success.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Alvarez, Elysia — University of California at Davis
- Study coordinator: Alvarez, Elysia
Related research
Other NIH-funded projects on the same topics.
-
AI-powered prognostic model for Ewing sarcoma using digital pathology
Researchers are building an AI tool to predict survival for children and adults with Ewing sarcoma using digitized pathology slides.
-
RAPID: A patient-centered, fast-tracked drug trial platform for young people with relapsed Ewing sarcoma and DSRCT
A patient-friendly, open-label phase 2 platform trial tests promising drug combinations for teens and young adults whose Ewing sarcoma or DSRCT has come back or not responded to treatment.
-
TGFβ brakes immune evasion and metastasis in Ewing sarcoma during radiation
A physician-scientist will study whether blocking TGFβ during radiation can help CAR T cells fight Ewing sarcoma and improve patient outcomes.
-
Function and Targeting of ETV6 in Ewing Sarcoma
A scientist at Case Western Reserve University is studying a specific protein, ETV6, that helps a rare bone cancer called Ewing sarcoma, with the goal of finding targeted therapies that could spare healthy cells.
-
Targeting immune markers in Ewing Sarcoma to guide safer, more effective therapies
A funded project at Stanford aims to use immune markers on Ewing Sarcoma to develop targeted immunotherapies that work in children and adults with this cancer.
-
Ewing sarcoma: how DNA repair weaknesses affect risk and treatment
A clinician-researcher team at Dana-Farber is studying how DNA damage repair weaknesses help drive Ewing sarcoma in kids and teens, with the goal of better predicting risk and guiding therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.